Stryker, a global leader in medical technologies, announced in May 2026 that it has acquired Amplitude Vascular Systems (AVS) for an undisclosed amount. AVS, now part of Stryker, is an early-stage medical device company founded in 2018 by Hitinder Gurm, M.D., and Robert Chisena, Ph.D. The company specializes in safely and effectively treating severely calcified arterial disease through its Pulse IVL System, which employs a novel pulsatile mechanism of action to shatter calcium and expand narrowed vessels with a single device.
This acquisition strategically enhances Stryker's extensive portfolio of innovative products and services across MedSurg, Neurotechnology, and Orthopedics. Stryker, driven to make healthcare better and impacting over 150 million patients annually, gains a specialized technology that addresses a critical need in interventional therapy. AVS's Pulse IVL System aligns with Stryker's mission to improve patient and healthcare outcomes by offering advanced solutions for complex medical conditions.
The integration of Amplitude Vascular Systems is expected to create significant synergies. Stryker's global market presence, robust commercial infrastructure, and deep customer relationships are anticipated to accelerate the development and broader adoption of AVS's innovative pulsatile intravascular lithotripsy technology. Conversely, AVS brings a unique and promising modality to Stryker's offerings, expanding its capabilities in the cardiovascular space.
Looking forward, the combined entity aims to redefine interventional therapy for severely calcified lesions. By leveraging Stryker's resources and AVS's specialized technology, the acquisition is poised to deliver enhanced treatment options, ultimately improving the quality of life for patients suffering from this challenging arterial disease.